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The pdx1 gene is essential for pancreatic organogenesis in humans and mice; pdx1 mutations have been identified in human diabetic patients.
Specific inactivation of pdx1 in adult β cells revealed that this gene is required for maintenance of mature β cell function. In the following study, a
Cre-lox strategy was used to remove pdx1 function specifically from embryonic β cells beginning at late-gestation, prior to islet formation. Animals
in which pdx1 is lost in insulin-producing cells during embryogenesis had elevated blood glucose levels at birth and were overtly diabetic by
weaning. Neonatal and adult mutant islets showed a dramatic reduction in the number of insulin+ cells and an increase in both glucagon+ and
somatostatin+ cells. Lineage tracing revealed that excess glucagon+ and somatostatin+ cells did not arise by interconversion of endocrine cell types.
Examination of mutant islets revealed a decrease in proliferation of insulin-producing cells just before birth and a concomitant increase in
proliferation of glucagon-producing cells. We propose that pdx1 is required for proliferation and function of the β cells generated at late gestation,
and that one function of normal β cells is to inhibit the proliferation of other islet cell types, resulting in the appropriate numbers of the different
endocrine cell types.
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Mature pancreatic islets are composed of five different
endocrine cell types (α: glucagon, β: insulin, δ: somatostatin, ε:
ghrelin, and PP: pancreatic polypeptide) arranged in a typical
architecture where the β cells, which make up the large majo-
rity, are found at the core and the other cell types are located at
the periphery or mantle. Pancreatic endocrine cells appear in⁎ Corresponding author. Department of Medicine, Division of Diabetes,
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doi:10.1016/j.ydbio.2007.10.038two waves during mouse pancreatic organogenesis (Pictet et al.,
1972; Pang et al., 1994). During the first wave, which begins at
embryonic day 9.5 (e9.5), the glucagon- and insulin-expressing
cells that arise differ in their gene expression pattern from the
mature cells found in adult islets. First wave glucagon-
producing cells express pro-hormone convertase 1/3 (PC1/3)
rather than PC2, which is expressed by mature α and β cells
(Lee et al., 1999; Wilson et al., 2002), and first wave insulin-
producing cells lack the glucose transporter, GLUT2, a marker
of mature β cells (Pang et al., 1994). Insulin/glucagon double-
positive cells have been detected at early developmental stages
and have been postulated to represent an intermediate stage of
endocrine differentiation (Alpert et al., 1988; Teitelman et al.,
1993). Lineage tracing studies, however, suggest that these cells
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al., 1994; Herrera, 2000). Thus, the function of these first wave
single and double hormone-positive cells remains unclear.
The second wave of endocrine differentiation occurs bet-
ween e13.5 and 16.5, and is believed to produce the cells of the
mature islets (Pictet et al., 1972; Pang et al., 1994). The mecha-
nism driving the relatively sudden increase in endocrine cell
formation at this particular time in development is unknown,
although signals including the Notch/Ngn3 pathway that affect
precursor proliferation and differentiation are likely to be
involved (Apelqvist et al., 1999; Murtaugh et al., 2003; Jensen,
2004). At late gestation and early postnatal stages, the islets
begin to adopt their characteristic core/mantle architecture.
Little is known about how the different endocrine cell types or
their precursors interact with one another to generate the correct
proportions of the various cell types. Several studies suggest
that early glucagon-producing cells are required specifically for
the generation of first wave insulin-producing cells (Dohrmann
et al., 2000; Prasadan et al., 2002; Vincent et al., 2003), but it is
uncertain whether similar cell–cell interactions are involved in
generating endocrine cells at the secondary transition.
Reverse genetic studies in mice are helping to elucidate the
complex pathways and gene interactions involved in pancreas
development (Wilson et al., 2003). Genetic or cell deletion
studies in the absence of lineage tracing techniques can, how-
ever, result in difficulties in deciphering cell differentiation
pathways. Loss of one cell population in a particular mutant
condition may have a profound non-cell autonomous effect on
another cell population. For example, selective deletion of PP-
producing cells, which results in the loss of both insulin- and
somatostatin-producing cells, could be explained either by a PP-
expressing precursor cell population giving rise to these two cell
types, or by PP-expressing cells producing an inductive signal
required for the production of β and δ cells (Herrera et al.,
1994). Lineage tracing analyses have helped distinguish bet-
ween these possibilities, and suggest that mature β cells do
indeed arise from cells that previously expressed PP (Herrera,
2000).
The homeobox gene pdx1 is expressed within the developing
pancreatic endoderm in all vertebrates so far examined (Gannon
and Wright, 1999). In the mouse, pdx1 expression begins at
e8.0 (Guz et al., 1995; Li et al., 1999), prior to the onset of
pancreatic bud formation and islet hormone gene expression,
and is initially detected throughout the pancreatic epithelium.
By late gestation, pdx1 expression is selectively maintained at
high levels in β cells, with low levels of expression in acinar
cells (Guz et al., 1995; Wu et al., 1997). Loss of pdx1 function
results in an early block in pancreatic outgrowth and
differentiation in both mice and humans (Jonsson et al., 1994;
Offield et al., 1996; Stoffers et al., 1997a,b). The pancreatic
rudiment of pdx1 null mouse embryos does contain transient,
first wave insulin+ cells (Ahlgren et al., 1996), and longer-lived
glucagon+ cells (Offield et al., 1996), indicating that pdx1 is not
required to generate first wave endocrine cells. In addition to an
early role in pancreatic bud outgrowth, studies using tetracy-
cline-inducible pdx1 inactivation demonstrated that pdx1 is also
specifically required between e11.5 and e13.5 in order forsubsequent differentiation of endocrine and exocrine cells
(Holland et al., 2002).
Mice heterozygous for a pdx1 deficiency are glucose-
intolerant (Ahlgren et al., 1998; Dutta et al., 1998; Brissova et
al., 2002), consistent with the finding that humans carrying
dominant pdx1 mutations are predisposed to a form of Type 2
diabetes called maturity onset diabetes of the young type 4
(MODY4) (Stoffers et al., 1997a,b, 1998; Macfarlane et al.,
2000). The continued essential role for pdx1 in mature β cells
(Ahlgren et al., 1998; Holland et al., 2002) fits well with its
identification as a direct activator of several β cell-specific
genes that control glucose utilization and metabolism, including
insulin, IAPP, glucokinase, Pax4, and pdx1 itself (Chakrabarti
et al., 2002; Cissell et al., 2002).
Direct evidence that pdx1 is essential for maintaining mature
β cell function comes from studies using tetracycline-inducible
pdx1 inactivation in adult mice (Holland et al., 2002) as well as
conditional inactivation studies using an insulin promoter-
driven Cre transgene that resulted in a loss of Pdx1 protein
between 3 and 5 weeks after birth (Ahlgren et al., 1998). This
mature β cell-specific loss of pdx1 caused a dramatic decrease in
insulin, Nkx6.1, and GLUT2 expression, a concomitant increase
in the number of glucagon+ cells, and overt diabetes in 3–
5 month old mice. The excess glucagon+ cells and large number
of insulin/glucagon co-producing cells that were detected in the
islets of these mice led to the suggestion that insulin+ cells
acquire glucagon expression after removal of the repressive
influences of Pdx1. In the absence of lineage tracing, it is
impossible to determine the origin of the excess glucagon+ cells.
One can envisage several ways in which such cells could arise
from β cells or an insulin-expressing precursor cell type: (1)
mature β cells de-differentiate to a more immature glucagon/
insulin co-expressing cell type; (2) β cells slowly trans-differ-
entiate towards a mature α cell type; or, (3) β cells loss promotes
generation of new endocrine cells from an unidentified
progenitor cell, which then gives rise to insulin/glucagon
double-positive cells.
In summary, therefore, while pdx1 is critical early in pan-
creas development for global organ formation and differentia-
tion, as well as later in mature β cells, it is unclear what role it
plays at the secondary transition in generating the β cells that
will contribute to mature islets. We report here the results of a
Cre-lox conditional inactivation study that provides details on
pdx1 function early in the definitive β cell lineage (during the
second wave of endocrine differentiation), in which we assessed
the consequences of pdx1 inactivation by including lineage-
tracing analysis. In this study, we used an optimized rat insulin
promoter-Cre transgenic line (RIP-Cre; Postic et al., 1999;
Gannon et al., 2000a,b,c) which shows functional recombina-
tion as early as e11.5 in developing pancreas and efficient
(N85% of β cells) excision of loxP-flanked DNA (Postic et al.,
1999; Gannon et al., 2000c). We demonstrate that loss of pdx1
from early β cells leads to a severe reduction in the number of
insulin+ cells beginning at late gestation stages. β cell-specific
inactivation of pdx1 during embryogenesis results in early-
onset diabetes, disrupted islet architecture, and increased
numbers of glucagon+ and somatostatin+ cells at the expense
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fate of cells that activated the RIP-Cre transgene. We provide
evidence for a linkage between the overall β cell number and
the mechanisms that control the proliferation/differentiation of
glucagon+ cells.
Materials and methods
Construction of floxed pdx1 allele and generation of mice
The pdx1tm4(E2)Cvw-TKneo targeting construct (see Fig. 1) was generated using
the pLox-TKneo vector (Orban et al., 1992). Standard subcloning methods were
used to introduce loxP sites into the intron and just after the poly-A addition site,
thus flanking the DNA binding domain-containing exon 2 (Fig. 1; details
available upon request). The integrity of pdx1 sequences and loxP sites was
checked by diagnostic restriction enzyme digestion and sequencing. Plasmid
DNA was CsCl-purified, the entire insert isolated by low-melt agarose gel
electrophoresis after NotI digestion, and purified using Gelase (Epicentre
Technologies).
200 μg of linearized pdx1tm4(E2)Cvw-TKneo DNAwas electroporated into TL1
129 SvEv ES cells by the Vanderbilt University Transgenic/ES Cell Core, andFig. 1. (A) Diagram of pdx1 locus, loxP-containing targeting construct, and expected
homeodomain, solid line: genomic regions used in targeting construct, open arrows:
promoter, stippled box: thymidine kinase cassette driven by the HSV promoter. Loca
locus. Restriction enzyme sites: B, BamHI; P, PstI; X, XbaI. Sites in parentheses are lo
targeting construct. (B) Southern blot of DNA from three representative neomycin-re
endogenous allele; 2.7 kb band, floxed allele. BamHI digest (right panel): 7.0 kb ba
electroporation.ES cell clones were grown as described (Hogan et al., 1994). Correctly targeted
ES cell clones were identified by Southern blot analysis of genomic DNA [PstI
or BamHI digest, 500 bp 3′ pdx1 cDNA internal probe (Figs. 1A, B); XbaI
digest, 550 bp XbaI–EcoRI external probe (data not shown)]. On PstI digestion,
the 3′ cDNA probe recognizes a 4.0-kb endogenous locus band and a 2.7-kb
band for the loxP-marked allele. BamHI digestion generates an endogenous
allele band of 7.0 kb or an 11.0 kb band from the loxP-marked allele. A total of
543 ES cell clones were screened with a targeting efficiency of 6.8%. Thus, 37
correctly targeted clones were identified. The 1B8 ES cell clone containing the
correctly targeted pdx1tm4(E2)Cvw-TKneo allele was electroporated with CMV-Cre
plasmid to remove the PGK-neoR/HSV-TK cassettes. Cre-mediated excision of
the selection cassette was determined using an 800 bp fragment of the neoR
cassette, which recognizes a 1.0 kb PstI band. The presence of exon two was
confirmed by retention of the 2.7 kb PstI band using the 3′ cDNA probe. One
clone undergoing the desired recombination event (1B8/10) was injected into
C57BL/6 blastocysts to generate chimeric mice. Male chimeras were bred to
Black Swiss females and agouti offspring were genotyped by Southern analysis
for transmission of the pdx1tm4(E2)Cvw allele (PstI digestion; 3′ pdx1 cDNA
probe) from here on termed pdx1flE2. pdx1flE2 heterozygotes were bred to
produce pdx1flE2/flE2 mice, which are phenotypically normal by several criteria
(see Results).
The RIP-Cre line used in these studies has been described (Postic et al.,
1999; Gannon et al., 2000c). RIP-Cre transgenics were identified by Southernproducts following Cre-mediated recombination. Black boxes: exons, gray box:
loxP sites, cross-hatched box: neomycin resistance cassette driven by the PGK
tion of internal and external probes for Southern blotting is indicated below the
st in the generation of the targeting construct. Sites in italics are introduced in the
sistant ES cell clones using internal probe. PstI digest (left panel): 4.0 kb band,
nd, endogenous allele; 11.0 kb band, floxed allele. Asterisk: clone used for Cre
409M. Gannon et al. / Developmental Biology 314 (2008) 406–417analysis (EcoRI digestion; 500 bp BamHI–ClaI Cre probe). R26R mice,
originally from Philippe Soriano (Soriano, 1999), were a gift of Richard
Behringer (M.D. Anderson Cancer Center, Houston, TX) and were genotyped
by Southern analysis (EcoRI digestion; 726 bp PvuI lacZ probe). RIP-Cre;
R26R bigenic mice were mated with mice heterozygous for the pdx1XBKo null
allele generated previously by our laboratory (Offield et al., 1996). We will refer
to these mice as pdx1+/−. pdx1+/−;RIP-Cre;R26R mice were generated at the
expected frequency of 1:8. The pdx1 null allele was identified by Southern
blotting (Offield et al., 1996). pdx1flE2/flE2 mice were bred to pdx1+/−;RIP-Cre;
R26R mice to generate pdx1flE2/−;RIP-Cre;R26R mice at a frequency of 1:8.
pdx1flE2/−;RIP-Cre mice will be referred to as pdx1ΔE2β. All animals were given
water and Lab Diet #5015 mouse pellets ad lib on a 12-h light/dark cycle.
Tissue preparation and histology
The morning of the vaginal plug was considered e0.5. Embryonic digestive
organs, including pancreata, were dissected in PBS and fixed immediately in
ice-cold 4% paraformaldehyde (4 °C; 45 min to 1 h). Tissues were dehydrated in
an increasing ethanol series and embedded in paraffin for sectioning. Serial 7 μm
sections mounted on glass slides with Sta-on (Surgipath) were used for
histology, immunohistochemistry, and immunofluorescence analyses. Analyses
were performed on at least five sections from each of at least three separate
animals. Frozen tissues were fixed as above, incubated in 30% sucrose overnight
at 4 °C, embedded in optimum cutting temperature compound (VWR Scientific,
West Chester, PA), and 5 μm sections were cut on a Leica CM 3050 S cryostat.
β-galactosidase detection
Following fixation, tissues were washed twice for 30 min in permeabiliza-
tion solution (2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% Nonidet P-40
in PBS). β-galactosidase (β-gal) activity was detected using X-gal as described
(Wu et al., 1997; Gannon et al., 2000a,b,c). Tissues were post-fixed and dehy-
drated for embedding as above, with isopropanol replacing xylene to minimize
leaching of the blue precipitate. Images were collected on an Olympus BX41
microscope with an Olympus digital camera and Magnafire program (Optronics,
Inc.). Images were all equivalently processed in Adobe Photoshop 6.0.
Immunohistochemistry and immunofluorescence
Sections were deparaffinized in xylene and rehydrated in a descending
ethanol series to water. Immunoperoxidase staining for insulin, glucagon, and
somatostatin was performed as previously described (Gannon et al., 2000b).
Primary antibodies were used at the following dilutions: guinea pig anti-bovine
insulin (Linco), 1:1000; rabbit anti-glucagon (Linco), 1:1000; guinea pig anti-
glucagon (Linco), 1:500; rabbit anti-human somatostatin (Dako), 1:1000; rabbit
anti-Pdx1, 1:25 (Peshavaria et al., 1994); rabbit anti-GLUT2 (a gift of Bernard
Thorens, University of Lausanne), 1:500; rabbit anti-phospho-histone H3, 1:50
(Upstate Biotechnology). Two different antibodies against β-galactosidase were
utilized: a rabbit anti-β-galactosidase generated against an XlHbox4-β-gal
fusion protein that specifically recognizes β-galactosidase on western blot
(Gannon et al., 2001), and rabbit anti-β-gal 1:5000 (MP Biomedicals). Antigen
retrieval [10 mM citrate buffer, microwave oven 3 min then 1 min at 1000 W,
20 min at room temperature] was performed for immunodetection of Pdx1,
GLUT2, phospho-histone H3, and β-gal. Samples were viewed under bright
field illumination and photographed with Kodak Ektachrome 64T film, or using
an Olympus BX41 microscope and digital camera (Magnafire program). For
immunofluorescence, donkey anti-guinea pig CY2 and donkey anti-rabbit CY3
or CY5 were used as secondary antibodies. CY2 was excited at 543 nm, CY3 at
488 nm, and CY5 at 647 nm using an LSM 410 confocal microscope (Zeiss).
Optical sections were taken at 1 μm. TIFF images from each experiment were
processed equivalently in Adobe Photoshop 6.0.
Glucose tolerance tests (GTT)
Intraperitoneal glucose tolerance tests were performed as described (Gannon
et al., 2000b). Following a 16-h fast, baseline blood glucose levels (mg/dl) were
measured in 10 μl tail vein blood from mildly anesthetized mice using the Accu-Chek Advantage glucose meter and Accu-Chek test strips (Roche). Glucose
(2 mg dextrose/g body weight) in sterile PBS was injected intraperitoneally and
blood glucose measured 15, 30, 60, 90 and 120 min after injection. GTT were
performed every 2 weeks for 2–4 months beginning at weaning. Insulin
radioimmunoassay was performed as previously described (Gannon et al.,
2000c).
Results
The floxed pdx1 allele functions as a wild type allele
In order to produce a conditional pdx1 null allele, loxP sites
were placed on either side of exon two, which encodes the DNA
binding homeodomain. The introduction of the 34 bp loxP se-
quences at these two locations did not interfere with pdx1 gene
function of the floxed allele. pdx1flE2/+ and pdx1flE2/flE2 animals
were born at the expected frequency, survived through adul-
thood, and were outwardly indistinguishable from control litter-
mates. In neonates and 1-month-old animals, the gross
morphology (size and shape) of the pancreata of pdx1flE2/+
and pdx1flE2/flE2 mice was identical to control littermates, as
was islet number, size, and architecture (data not shown). On
intraperitoneal glucose tolerance test (IP-GTT), animals of all
three genotypes (+/+, flE2/+, flE2/flE2) had a fasting blood
glucose level in the normal range (70–150 mg/dl) and effi-
ciently cleared a glucose bolus from the bloodstream, returning
to baseline glucose levels within a 2-h period (data not shown).
We conclude that the floxed pdx1 allele is a true conditional
null allele with wild type function in the non-recombined
configuration.
RIP-Cre mediated pdx1 inactivation occurs during embryonic
stages
To inactivate pdx1 specifically in embryonic pancreatic β
cells, mice carrying the floxed pdx1 allele were bred to mice
carrying a RIP-Cre transgene. Inclusion of the R26R reporter
allele, in which expression of a lacZ reporter cassette depends
upon Cre-mediated removal of a loxP-flanked “stop” sequence
(Soriano, 1999), allowed the detection of cells that have under-
gone recombination in our experiments. Using R26R mice, we
previously characterized the RIP-Cre transgene as being active
in isolated pancreatic cells at e11.5 and restricted to insulin-
producing cells of the pancreas at all times examined (Gannon
et al., 2000c). At P1 and in adults, recombination-based
activation of β-gal expression was detected inN85% of
insulin-producing cells in the islet core. Expression was never
observed in glucagon-expressing cells, acinar cells, or other
cells of the foregut.
We reasoned that placing the pdx1flE2 allele in trans with a
pdx1 null allele (Offield et al., 1996) would require Cre-
mediated inactivation of only a single floxed pdx1 allele,
facilitating the generation of pdx1 null β cells (pdx1ΔE2β). To
this end, pdx1+/− mice were bred to RIP-Cre;R26R mice (see
Methods). Matings between pdx1+/−;RIP-Cre;R26R mice and
pdx1flE2/flE2 mice generated pdx1flE2/−;RIP-Cre and pdx1flE2/−;
RIP-Cre;R26R experimental mice, both at the expected fre-
quency of 1:8. On average, therefore, one quarter of the pups
Fig. 2. Loss of PDX1 in insulin-producing cells in pdx1ΔE2β;R26R embryos.
(A) Sections from control pancreata at e14.5 show intense PDX1 protein
expression (red) in the nuclei of most insulin+ cells (green; arrows). (B) In
pdx1ΔE2β, most insulin+ cells showed no detectable PDX1 protein (yellow
arrowheads), although PDX1+/insulin+ cells are present (arrow). Weaker PDX1
expression is observed in ducts and developing acinar cells in all embryos. (C)
PDX1 protein is apparent in most nuclei of β-gal expressing (i.e., recombined/
red) β cells of e18.5 RIP-Cre;R26R embryos. (D) In pdx1ΔE2β animals,
recombined (β-gal+/red) cells no longer express PDX1. (E) In control embryos,
proliferation, identified using a phospho-histone H3 antibody (green), is
observed in some recombined β cells (red) at e18.5 (arrows). (F) β cells that
have lost PDX1 (red cells) are not proliferating, although other cells within the
same field are (green nuclei).
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pdx1 (from here called pdx1ΔE2β), and half of these pups
would also carry the activatable β-gal lineage marker. The
phenotypes of both pdx1ΔE2β and pdx1ΔE2β;R26R mice were
identical, indicating that the presence of the R26R allele had no
effect on the function of the Cre transgene, or on the con-
sequences of pdx1 inactivation. In the subsequent studies, mice
of both genotypes were used interchangeably, except for the
lineage studies, which required pdx1ΔE2β and R26R in
combination.
Based on the detection of RIP-Cre activity by R26R
activation, we anticipated that pdx1 inactivation would occur
early in the great majority of insulin-producing cells. The pre-
vious analysis of pdx1 null mutant animals revealed the
presence of significant numbers of pdx1-independent first
wave insulin- and glucagon-positive cells (Ahlgren et al., 1996;
Offield et al., 1996). In the current study, pancreata from
pdx1ΔE2β, pdx1ΔE2β;R26R embryos, and control littermates
(pdx1+/−;RIP-Cre, pdx1flE2/+;RIP-Cre, and pdx1flE2/−) were
examined during the second wave of endocrine differentiation,
beginning at e14.5, to assess the effects of Cre-mediated pdx1
inactivation on the formation of endocrine cells that would go
on to contribute to the mature islets.
Initially, we examined embryos at e14.5 to determine
whether RIP-Cre mediated recombination resulted in the loss
of Pdx1 protein expression from insulin-producing cells. At this
time point, the majority of insulin-positive cells should have
been generated from the second wave of endocrine differentia-
tion. In sections from control pancreata (n=7) at this stage,
nuclear Pdx1 protein was detected in 78% of insulin+ cells
(n=132/170; Fig. 2A), while only 46% of insulin+ cells in the
e14.5 conditional mutant (n=3) pancreas co-expressed Pdx1
(n=26/57; Fig. 2B) indicating that some insulin-producing cells
have already undergone recombination and lost Pdx1 expres-
sion at this stage. The average number of insulin+ cells per
section was identical in both mutant and control pancreata at
this stage. At e17.5–e18.5, Pdx1 was detected in 75% of in-
sulin+ cells (n=280/374) of control embryos (n=3). In contrast,
only 19% of insulin+ cells (n=87/453) in mutant embryos (n=
4) had detectable levels of Pdx1 at these stages (data not shown)
indicating that recombination of the pdx1flE2 allele has occurred
in the majority of insulin-producing cells by late gestation. At
postnatal day 2, 15% of insulin+ cells found in mutant pancreata
still contain detectable levels of Pdx1 protein (data not shown),
in agreement with our previously published results showing that
this RIP-Cre line mediates recombination in ∼85% of β cells
(Gannon et al., 2000c).
Since lineage tracing of pdx1 null mutant cells relies on
equivalent efficiencies of recombination for both the pdx1flE2
and the R26R alleles, we next wanted to determine whether the
dramatic Cre-mediated loss of PDX1 expression seen at e17.5–
e18.5 was always associated with activation of the R26R allele.
In RIP-Cre;R26R control pancreata (n=4 animals) at e18.5,
Pdx1 was detected in 90% of recombined (i.e. β-gal+) nuclei
(Fig. 2C), consistent with its high level of expression in normal
insulin-producing cells (Gamer and Wright, 1995; Guz et al.,
1995). In contrast, Pdx1 was not observed in β-gal+ cells inpancreata from pdx1ΔE2β;R26R embryos at e18.5 (n=3
animals), indicating that recombination of both the R26R and
pdx1flE2 allele occurred in the same cells and that any residual
Pdx1 protein in these cells is below the level of detection in
tissue from late gestation stage embryos (Fig. 2D). Since re-
combination of both the pdx1flE2 and the R262R alleles appears
to be coincident, the insulin+ cells present in e17.5–e18.5 mu-
tant pancreata that still contain Pdx1 protein most likely
represent newly generated β cells or β cells that are refractory to
recombination (Gannon et al., 2000c). Pdx1+/β-gal− cells were
present within pancreata from both control and mutant animals
(Figs. 2C, D). These cells likely represent a combination of un-
recombined insulin+ cells, other endocrine cell types known to
express Pdx1, acinar clusters, and ductal epithelial cells,
although acini and ducts usually expressed lower levels of the
protein.
Because increased Pdx1 expression has been associated with
proliferation of ductal and islet cell populations (Sharma et al.,
1999; Song et al., 1999), we examined the effect of β cell pdx1
Fig. 3. Early loss of pdx1 in β cells results in diabetes post-weaning. (A) Male
animals (upper panel) in which pdx1 has been inactivated in β cells (Bcell KO:
pdx1ΔE2β) are diabetic when compared with control littermates. In control
animals (gray line), blood glucose levels return to baseline during the course of
an IPGTT, while in the pdx1 β cell knockout animals, blood glucose levels
remain elevated throughout the test (black line). Female pdx1ΔE2β mice (lower
panel) show only a mild impairment in glucose tolerance compared with
controls. (B) While control animals show increased plasma insulin levels 15 min
after glucose injection (left bars), plasma insulin levels remain at fasting levels in
pdx1ΔE2β animals (right bars).
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histochemical detection of phosphorylated histone H3 (pH3), an
M-phase-specific marker of actively dividing cells (Gurley et
al., 1978). In e18.5 pdx1ΔE2β pancreata, β-gal+ cells (assumed
to be Pdx1−) were always observed to be pH3-negative (Fig.
2F), whereas 8% of β-gal+ cells in control pancreata of the same
age were observed to be actively proliferating (Fig. 2E). Mutant
pancreata did not show a global defect in proliferation, since β-
gal− cells were observed to be actively proliferating (Fig. 2F).
We conclude that the defect in proliferation was restricted to
cells that had undergone RIP-Cre-mediated pdx1 inactivation
and no longer expressed Pdx1 protein.
Loss of pdx1 from β cells causes functional and morphological
abnormalities in islets
β cell-specific inactivation of pdx1 during embryogenesis
resulted in very early onset diabetes. As early as postnatal day
one (P1), plasma glucose levels during ad lib feeding were
between 225 and 350 mg/dl in mutant pdx1ΔE2β mice (n=3),
while control littermates had plasma glucose levels of 100–
165 mg/dl with a mean of 145 mg/dl (n=12). Despite the ele-
vated blood glucose, pdx1ΔE2β mice survived past weaning and
into adulthood (at least to 8 months, the longest we have main-
tained the mutant animals).
As adults (1–5 months of age), pdx1ΔE2β male mice showed
β cell dysfunction when assessed by intra-peritoneal glucose
tolerance test (IP-GTT). pdx1ΔE2β male mice (n=5) had an
average fasting blood glucose level of 335 mg/dl (range: 180–
475 mg/dl). Upon IP administration of glucose, circulating
glucose levels in pdx1ΔE2β mice became further elevated and
remained high over the test period (Fig. 3A). The average 2-h
postprandial glucose measurement was 490 mg/dl. In contrast,
control mice (n=11) had an average fasting blood glucose level
of 98 mg/dl (range: 60–117 mg/dl) and an average 2-h
postprandial glucose measurement of 209 mg/dl. Importantly,
animals carrying the RIP-Cre transgene alone showed no
defects in glucose clearance (data not shown) as has been
reported for this transgene on some genetic backgrounds (Lee et
al., 2006). pdx1ΔE2β male and female mice had dramatically
decreased plasma insulin following glucose administration (Fig.
3B). In control mice, plasma insulin levels ranged from 225 to
495 pg/ml 15 min after glucose injection (n=6), while plasma
insulin in pdx1ΔE2β animals ranged from 100 to 170 pg/ml
(n=4), which is similar to the fasting plasma insulin levels of
wild type mice (Fig. 3B). Despite having a reduced number of β
cells and reduced plasma insulin levels comparable to males,
pdx1ΔE2β female animals showed only a mild glucose into-
lerance relative to control female animals (Fig. 3A). This sexual
dimorphism in susceptibility to diabetes has been demonstrated
in other rodent models of diabetes (Ostenson et al., 1989; Bell et
al., 1994; Zhang et al., 2006).
Confocal immunofluorescence analysis at 1 month of age,
when animals are already overtly diabetic, revealed several
defects in mutant islets compared with controls (Fig. 4). The
numbers of glucagon+ and somatostatin+ cells were increased
(Figs. 4B, D). There was no change in the number of PP cells(data not shown). We were unsuccessful in our attempts to
analyze ghrelin expression using currently available antibodies.
Thus, it remains possible that pdx1-null β cells are able to con-
vert to ghrelin-expressing cells in islets from pdx1ΔE2β animals
as observed in other mouse models of embryonic β cell loss
(Prado et al., 2004). The excess α and δ cells did not co-express
insulin (Fig. 4F and data not shown), in contrast to the study
performed by Ahlgren et. al. (1998) in which inactivation of
pdx1 in adult insulin-expressing cells led to large numbers of
glucagon/insulin co-expressing cells. In addition, both gluca-
gon+ and somatostatin+ cells were scattered throughout the
islets and not localized to the periphery as in control islets.
Third, the level of insulin immunoreactivity in the remaining
insulin+ cells was reduced, in agreement with the radio-
immunoassay data (Fig. 4F).
Fig. 4. Loss of pdx1 in the β cell lineage leads to aberrant islet architecture, and
increased numbers of glucagon- and somatostatin-producing cells. Confocal
analysis reveals that compared to control animals at 1 month of age (A, C), islets
of pdx1ΔE2β animals have increased numbers of glucagon+ cells (B) and soma-
tostatin+ cells (D) that are scattered throughout the islets. pdx1ΔE2β animals also
have fewer insulin+ cells (green) when compared with controls (E, F). Insulin
and glucagon are not co-expressed (F).
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our model suggests two possibilities: 1. β→α or δ conversion
initiates earlier in development and is complete by the time weFig. 5. Alterations in the proportion of α and β cells in pdx1ΔE2β animals are first app
indicates that the proportion of α and β cells is identical in control and pdx1ΔE2β emb
of the α cell population and decline in the β cell population begins at e18.5 (compare
majority of cells express either one hormone or the other. Cells co-expressing bothexamined them at 1 month of age, or, 2. the excess glucagon+
and somatostatin+ cells we observe in our model do not arise
from a cell that previously expressed insulin. The subsequent
studies address each of these possibilities.
Expansion of the α cell population in mutant pancreata is
observed at e18.5
We used confocal immunofluorescence analysis of pancreata
from several stages (gestation, birth, and up to 1 month of age)
to determine when the increase in glucagon-expressing cells
could be detected, and whether significant numbers of insulin+/
glucagon+ cells exist at any stage in our mutant pancreata. In
contrast to the finding in islets at 1 month of age, there was no
significant difference in the number of glucagon+ cells between
control and pdx1 β cell knockout pancreata at e14.5 or e17.5
(Figs. 5A and E, and data not shown). The earliest time at which
increased numbers of glucagon+ cells could be distinguished in
mutant pancreata was e18.5 (Figs. 5B and F). By P1, the
increased proportion of glucagon+ cells was dramatic (compare
Figs. 5C, D with G, H). The timing of this increase in glucagon+
cells correlated with a severe reduction in the number of insulin-
producing cells per islet. In both control and pdx1ΔE2β mutant
pancreata, clusters of insulin+ cells also expressed GLUT2, a
marker of second wave β cells, at the membrane at sites of β
cell-β cell contacts (data not shown). GLUT2 expression was
not detected in insulin− cells.
No glucagon/insulin co-expressing cells were detected at any
embryonic time point examined (e14.5, e17.5, e18.5) in either
control or mutant pancreata. At P1, very few cells (0.1% of all
glucagon+ cells; arrowheads in Figs. 5G and H) co-expressing
insulin and glucagon were detected within mutant islets, a fre-
quency that was consistent across many tissue sections sampled
from several different animals. Thus, we find no evidence for
significant numbers of glucagon/insulin co-expressing cellsarent at e18.5. Confocal analysis of insulin (green) and glucagon (red) expression
ryos at e14.5 (compare panel Awith panel E) and e17.5 (not shown). Expansion
panel B with panel F) and continues into postnatal development (G, H). The vast
hormones are occasionally detected (arrowheads in panels G and H).
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when this expansion first becomes apparent. These results are
inconsistent with the idea that the excess glucagon+ cells arose
via a transitional cell type in which insulin-producing cells
convert to glucagon-producing cells. This type of analysis,
however, cannot exclude the possibility that the β→α tran-
sition occurs too rapidly to be detected at the chosen static time
points. To determine more directly whether the excess gluca-
gon+ and somatostatin+ cells present within the β cell knockout
islets arose from cells that expressed insulin at an earlier time
point, we performed lineage-tracing analyses using the R26R
reporter mouse.
Excess glucagon+ and somatostatin+ cells do not arise from
insulin-producing cells
In RIP-Cre;R26R mice, Cre-mediated β-gal expression is
detected specifically in cells that activated the rat insulin pro-
moter transgene. The cell type-independence of the ROSA26
promoter means that progeny of the original cell undergoing
recombination stably inherit β-gal expression. Therefore,
because the ROSA26 promoter is active in all pancreatic endo-
crine cell types (Gannon et al., 2000a,c; Kawaguchi et al.,
2002), cells derived from insulin-expressing cells should be
detectable regardless of their subsequent insulin expression
status.
In RIP-Cre;R26R control pancreata from P1 animals, β-gal
expression was restricted, as expected, to insulin-producing cells
in the islet core (Figs. 6A, C), and absent from glucagon- and
somatostatin-producing cells. At P1,N90% of somatostatin+
cells were β-gal−(Fig. 6C), we did detect co-expression ofFig. 6. Lineage tracing analysis at P1 reveals that excess glucagon+ and
somatostatin+ cells in pdx1 β cell knockout animals do not arise from insulin-
producing cells. In RIP-Cre;R26R control animals (A, C), insulin-producing
cells located at the core of the islet express β-gal (green) as expected. Glucagon+
(A) and somatostatin+ (C) cells (red) are located at the periphery and do not co-
express β-gal. In pdx1ΔE2β animals, the number of β-gal expressing cells is
dramatically reduced (B, C). β-gal expression does not co-localize with
glucagon (B) or somatostatin (C) indicating that these cells derive from cells that
did not express RIP-Cre.somatostatin and β-gal in∼8% of δ cells (n=12/156) in control
pancreata (data not shown). The small percentage of
somatostatin+ cells expressing β-gal could reflect leakiness of
the RIP-Cre transgene in this lineage, or alternatively, that a
proportion of δ cells may arise from an insulin/somatostatin co-
expressing intermediate, as suggested previously (Fernandes et
al., 1997; Sosa-Pineda et al., 1997). In P1 pdx1ΔE2β pancreata,
very few β-gal+ cells were detected within the islets (Figs. 6B,
D), consistent with the vast decrease in insulin+ cells noted
above (e.g. Fig. 5G). Significantly, the β-gal+ cells present at
P1 do not co-express either glucagon (0.2%; n=2/849) or
somatostatin (0.7%; n=1/142), indicating that the excess α and
δ cells did not arise from cells that were previously insulin-
producing. Taken together, these data suggest that the increase
in glucagon+ and somatostatin+ cells in pdx1ΔE2β pancreata is
likely caused by increased proliferation of these cell types or
their precursors, and not by conversion of pdx1 null “former-β
cells” to other endocrine cell types.
We next analyzed the proliferation status of differentiated
endocrine cells during the second wave of endocrine differ-
entiation (e14.5, e17.5, and e18.5). This developmental window
represents the time during which the proportions of the endo-
crine cell types become abnormal in the conditional mutant
animals. pH3-immunopositive cells were scored on at least ten
tissue sections containing endocrine cells from two litters at
each developmental time point. We failed to detect any differ-
ence in proliferation between control (n=4) and mutant (n=2)
pancreata at e14.5 (data not shown). Compared with wild type
pancreata (n=2), a three-fold increase in pH3-positive gluca-
gon+ cells [2% (n=2/113): wild-type; 6% (n=47/755): mutant]
was first detected at e17.5 in β cell knockout pancreata (n=3)
and was maintained at e18.5 (Figs. 7A–C and data not shown).
The proportion of proliferating insulin+ cells at e17.5 (∼1–2%;
data not shown) was indistinguishable between control (n=2/
196) and mutant (n=7/410) pancreata but, at e18.5, was drama-
tically reduced in conditional mutant tissue (10% in wild-type
n=43/438, 2% in mutants n=12/538; Figs. 7D, E). Proliferation
rates in the acinar tissue were not different between control and
mutant pancreata. We also examined whether insulin+ cells in
mutant pancreata were undergoing apoptosis. TUNEL labeling
was performed on control and mutant pancreata from e14.5 and
e18.5 embryos, P1 and adult. At no time point did we observe
apoptotic insulin+ cells in either control or mutant animals (data
not shown).
Discussion
The findings we report here add to our understanding of the
continual requirement for pdx1 in the life history of β cells. The
accumulating evidence demonstrates that Pdx1 plays essential
regulatory roles both during global pancreas formation and
specifically in β cells during embryonic and adult stages. Ho-
mozygous null pdx1 mice have a very early block in pancreas
development, but do undergo limited bud outgrowth (Offield
et al., 1996). These animals form neither mature islets nor acinar
tissue (Jonsson et al., 1994; Offield et al., 1996). Thus, pdx1 is
not required to specify the pancreatic field or to initiate
Fig. 7. Loss of pdx1 in the β cell lineage results in increased proliferation of glucagon+ cells and decreased proliferation of insulin+ cells. Co-labelling of e17.5 and
e18.5 pancreatic sections for either glucagon (green, A–C) or insulin (green, D–F) and phospho-histone H3 (red, A–F) reveals that in pdx1ΔE2β animals, the fraction of
proliferating α cells is increased at e17.5 (compare arrowheads in panel Awith panels B, C), while the proportion of insulin-expressing β cells actively proliferating is
dramatically decreased at e18.5 (compare arrowheads in panel D with panels E, F). No difference was observed at e14.5 (not shown).
414 M. Gannon et al. / Developmental Biology 314 (2008) 406–417outgrowth from the endodermal epithelium. Loss of pdx1 func-
tion after initial pancreatic bud outgrowth, using a doxycycline-
inducible system, results in a block in further pancreas
development (Holland et al., 2002), while pdx1 inactivation at
later embryonic stages results in a specific defect in develop-
ment of the exocrine pancreas (Hale et al., 2005). These studies
did not evaluate the effects of pdx1 removal on second wave
endocrine differentiation and expansion. Inactivation of pdx1
specifically in mature, adult β cells results in diabetes, loss of β
cell markers such as Nkx6.1 and GLUT2, and a great decrease
in the number of insulin-producing cells (Ahlgren et al., 1998;
Holland et al., 2002). Thus, neither the whole animal pdx1
knockout studies, nor the published conditional inactivation
studies address the requirement for pdx1 specifically during late
gestation, the time during which the majority of the insulin-
producing cells that will give rise to the mature islet are
generated.
pdx1 function in late gestation β cells differs from its function
in adult β cells
The current study is the first to define a role for pdx1 in the
late gestation embryonic β cells that are assumed to incorporate
into mature islets. In these studies, we used a Cre transgenic line
defined via R26R activation for its early and efficient
expression in insulin-producing cells within the pancreas. In
addition, we included the first lineage-tracing of pdx1-deficient
cells, and studies of the effect of pdx1 inactivation on cell pro-
liferation. Mice in which pdx1 was specifically inactivated in β
cells during embryogenesis showed a decrease in proliferation
of insulin+ cells at late gestation that translated into a decreased
number of β cells. pdx1ΔE2β animals showed a concomitant
increase in proliferation of glucagon+ cells at late gestation,
elevated postprandial blood glucose levels in neonates, and
overt diabetes at weaning.Although both the current study and the one performed by
Ahlgren et. al. (1998) used a similar strategy to inactivate pdx1
in the β cell lineage, Cre-mediated recombination in our study
occurred much earlier in the life history of the β cell. Thus, in
our experimental system, loss of Pdx1 was observed in a
substantial number of insulin-producing cells at e14.5, while a
significant decrease in Pdx1 expression was not detected until
3–5 weeks postnatally in the Ahlgren study. This difference in
the timing of pdx1 inactivation is perhaps due to a higher
efficiency of recombination driven by our RIP-Cre transgene, or
because our experimental design required inactivation of only
one floxed pdx1 allele to reach the null condition. Although it is
difficult to rule out, we believe it is less likely that the large
difference in timing of pdx1 inactivation between the two
studies is related to differences in the genetic background of the
various mice involved.
The fortuitous production of two models of β cell-specific
pdx1 inactivation has therefore revealed specific requirements
for pdx1 in embryonic and adult β cells. In the study by Ahlgren
et. al. (1998), pdx1 inactivation specifically in mature β cells
resulted in a reduced number of insulin-producing cells and an
associated increase in the number of glucagon-expressing cells,
a large fraction of which co-expressed both hormones, leading
to the hypothesis that insulin-producing cells were converting to
glucagon-producing cells following loss of Pdx1 protein. We
also observed a large increase in glucagon+ cells, as well as
somatostatin+ cells, following the selective inactivation of pdx1
in embryonic β cells. This increase in α and δ cell number was
apparent as early as e18.5. Lineage tracing of pdx1 null cells
revealed that these excess α and δ cells did not arise from
insulin-producing cells. Thus, loss of pdx1 in late gestation β
cells affects these cells differently from loss of pdx1 in a mature
β cell.
The increase in α cell number is associated with increased
proliferation of glucagon-producing cells and a decrease in
Fig. 8. Model of pancreatic endocrine differentiation and endocrine lineage
relationships (solid black lines indicate direct linage relationships, while dashed
black lines indicate presumed relationships). Endocrine cells arise from ngn3-
expressing progenitors regardless of whether they are generated in the first or
second wave of endocrine differentiation. In the first wave, which begins at
around e10.5 in the mouse, immature endocrine cells are generated, some of
which co-express insulin and glucagon. The fate of these cells is currently
unknown, however some studies suggest that the early glucagon+ cells function
in the generation of early insulin+ cells (gray arrow). In the second wave of
endocrine differentiation, which begins at around e14.5, mature endocrine cells
are generated. These cells arise from a PDX1+ cell. The α cell lineage is thought
to diverge early, while the existence of a multi-hormone positive cell that gives
rise to β, δ, and PP cells has been observed. Mature β cells (and presumably δ
cells) arise from a PP-expressing precursor. A paracrine effect of PP cells on δ
cell development has not been ruled out (dashed gray arrow). In the current
study, we have evidence for an inhibitory effect of β cells on the differentiation/
proliferation of α and δ cells (gray lines).
415M. Gannon et al. / Developmental Biology 314 (2008) 406–417proliferation of insulin-producing cells. Other studies have
shown an association between pdx1 and proliferation of pan-
creatic cells (Ahlgren et al., 1996; Sharma et al., 1999; Hart
et al., 2000), consistent with a loss of pdx1 leading to decreased
proliferation in the β cell lineage. Intriguingly, the reduction in
insulin-producing cells in mutant animals was most dramatic at
P1 and 1 week. By 1 month of age, we consistently observed an
increase in the number of insulin+ cells (compare Figs. 4 and 5).
Because the RIP-Cre transgene used here reproducibly showed
activity in approximately 85–90% of β cells at P1 (Gannon et
al., 2000c; Sund et al., 2001), it is possible that a population of β
cells is refractory to recombination and thus maintains PDX1
expression. These insulin+/Pdx1+ cells likely remain capable of
proliferating since β cell mass continues to increase even after
weaning via replication of pre-existing β cells (Kaung, 1994;
Finegood et al., 1995). Thus, the clusters of insulin+ cells
observed in adult mutant islets may represent clonal expansion
of unrecombined β cells.
Lineage tracing provides information about the fate of mutant
cells
Organogenesis involves the gradual restriction of potential
cell fate from multi-potency towards expression of specific
differentiated cellular phenotypes. A general regulatory princi-
ple for such programs is the sophisticated interplay between
cell-autonomous processes and intercellular communication.
The current study suggests a previously unappreciated interac-
tion between β cells and other endocrine cells (α and δ) or their
progenitors that establishes the appropriate proportions of en-
docrine cells during islet development. The R26R lineage tracer
revealed that the excess glucagon+ or somatostatin+ cells we
observe in pdx1ΔE2β mutants did not arise from β cells. This
finding leads to the idea that the decrease in β cell number
results from an increased flux from multipotential or lineage-
restricted endocrine progenitors towards the α/δ cell fates, and/
or an increased rate of proliferation of differentiated non-β cells
in the absence of appropriate numbers of β cells.
All five of the islet endocrine cell types are currently be-
lieved to derive from a common multipotential precursor, al-
though confirmation of this hypothesis awaits rigorous testing
by lineage-tracing techniques. Regardless, endocrine cells arise
from progenitors that at some time in their history expressed
pdx1 and ngn3 (Gu et al., 2002). The production of the five
major endocrine cell types must be regulated in order to con-
sistently produce the proportions seen in normal mature islets.
Presumably, environmental cues and lineage-specific combina-
tions of regulatory factors modulate the direction of differentia-
tion of multipotent or lineage-restricted amplifying populations
towards one endocrine cell type or another. Very little is known
about these instructive processes. Our findings are consistent
with a type of feedback effect whereby β cells regulate α cell
proliferation in a paracrine fashion (Fig. 8), and we propose a
similar mechanism to be responsible for the increased numbers
of somatostatin+ cells in β cell-specific pdx1 knockout animals.
A previous study in which insulin-producing cells were spe-
cifically ablated using a toxic β cell-specific transgene did notshow an effect on the development of α and δ cells (Herrera et
al., 1994). In that study, however, endocrine differentiation was
assessed only at e16.5, and it is possible, based on our findings,
that this is prior to the time at which an effect of β cell loss on α
and δ cell development would begin to be apparent. While the
nature of the β cell-derived paracrine inhibitory signal is un-
known, it is unlikely to be insulin itself since mice lacking both
insulin genes show normal numbers of α cells (Duvillie et al.,
1997, 2002).
Combining gene inactivation with lineage tracing allows one
to determine which, if any, developmental pathways are still
open to cells that have lost a particular gene product. For
example, the original global inactivation of Ptf1a concluded
that this gene is required for generation of the exocrine pancreas
416 M. Gannon et al. / Developmental Biology 314 (2008) 406–417(Krapp et al., 1998). Lineage-tracing studies using Cre-
mediated R26R activation (Kawaguchi et al., 2002), showed a
previously unappreciated expression of Ptf1a in precursors of
both exocrine and endocrine cells. In homozygous mutants,
lineage tracing revealed a conversion of most Ptf1a-deficient
pancreatic progenitors into normal duodenal cell fates. Simi-
larly, analysis of Pax6 mutant animals using hormone expres-
sion as an indicator of endocrine differentiation led to the
conclusion that Pax6 is required for differentiation of α cells
and normal numbers of other endocrine cell types (Sander et al.,
1997; St-Onge et al., 1997). Conditional inactivation of Pax6 in
the pancreas combined with lineage tracing of null mutant cells
revealed that normal numbers of endocrine cells actually form
in the mutant animals, but that these cells lack certain critical
terminal differentiation markers, resulting in impaired α and β
cell function (Ashery-Padan et al., 2004).
In addition to lineage-restricted transcriptional regulators
(reviewed in (Wilson et al., 2003), it is becoming apparent that
pancreatic endocrine cell development depends on interactions
and communications between the different islet endocrine
lineages (Herrera et al., 1994; Prasadan et al., 2002; Vincent et
al., 2003). Additional work is needed to define the nature of the
signals produced by the different islet endocrine lineages and
how these signals promote differentiation and proliferation to
yield fully functional islets.
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